H7N9 Mix and Match With MF59 in Healthy Adults

This is a Phase II randomized, double-blinded, controlled study in up to 700 males and
non-pregnant females, 19 to 64 years old, inclusive, who are in good health and meet all
eligibility criteria. The study is designed to assess the safety, reactogenicity, and
immunogenicity of a monovalent influenza A/H7N9 virus vaccine manufactured by sanofi pasteur
administered to healthy adults at different dosages (3.75, 7.5, or 15 mcg of HA/0.5 mL dose)
given with MF59 adjuvant manufactured by Novartis Vaccines and Diagnostics and without
adjuvant (15 mcg of HA/0.5 mL dose and 45 mcg of HA/0.75 mL dose). The A/H7N9 vaccine was
made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Subjects will be
randomly assigned to 1 of 7 groups (up to 100 subjects per group) to receive two doses of
the A/H7N9 vaccine with and without MF59 adjuvant delivered intramuscularly approximately 21
days apart. The same dosage of A/H7N9 vaccine will be given to subjects at both their first
and second study vaccinations. The primary objectives are to: 1) assess the safety and
reactogenicity of a monovalent influenza A/H7N9 virus vaccine following receipt of two doses
administered with and without MF59 adjuvant; and 2) assess new-onset chronic medical
conditions following receipt of two doses of a monovalent influenza A/H7N9 virus vaccine
administered with and without MF59 adjuvant. The duration of the study for each subject will
be approximately 13 months.

Inclusion Criteria:

- Provide written informed consent prior to initiation of any study procedures.

- Are able to understand and comply with planned study procedures and be available for
all study visits.

- Are males or non-pregnant females, 19 to 64 years old, inclusive.

- Are in good health, as determined by vital signs (oral temperature, pulse, and blood
pressure), medical history, and targeted physical examination based on medical
history to ensure any existing medical diagnoses or conditions (except those in the
Subject Exclusion Criteria) are stable. Subjects may be on chronic or as needed
(prn) medications if, in the opinion of the site principal investigator or
appropriate sub-investigator, they pose no additional risk to subject safety or
assessment of reactogenicity and immunogenicity. Note: Topical, nasal, and inhaled
medications (with the exception of steroids as outlined in the Subject Exclusion
Criteria (see section 5.2)), vitamins, and contraceptives are permitted.

- Oral temperature is less than 100.4 degrees F.

- Pulse is 50 to 115 bpm, inclusive.

- Systolic blood pressure is 85 to 150 mmHg, inclusive.

- Diastolic blood pressure is 55 to 95 mmHg, inclusive.

- Female subjects of childbearing potential who are not surgically sterile via tubal
sterilization, bilateral oophorectomy, or hysterectomy or who are not postmenopausal
for >/= 1 year must agree to practice highly effective contraception that may
include, but is not limited to, abstinence from intercourse with a male partner,
monogamous relationship with a vasectomized partner, male condoms with the use of
applied spermicide, intrauterine devices, and licensed hormonal methods with use of a
highly effective method of contraception for a minimum of 30 days prior to study
product exposure and agree to practice highly effective contraception for the
duration of study product exposure, including 2 months (defined as 60 days)after the
last study vaccination. A highly effective method of contraception is defined as one
which results in a low failure rate (i.e., less than 1 percent per year) when used
consistently and correctly. Method of contraception will be captured on the
appropriate data collection form.

- Female subjects of childbearing potential must have a negative urine or serum
pregnancy test within 24 hours prior to study vaccination.

Exclusion Criteria:

- Have an acute illness within 72 hours prior to study vaccination.

- Have any condition that, in the opinion of the site principal investigator or
appropriate sub-investigator, would place the subject at an unacceptable risk of
injury, render the subject unable to meet the requirements of the protocol, or
confound the interpretation of the results.

- Have an acute or chronic medical condition that, in the opinion of the site principal
investigator or appropriate sub-investigator, would render vaccination unsafe, or
would interfere with the evaluation of responses.

- Have immunosuppression as a result of an underlying illness or treatment, or use of
anticancer chemotherapy or radiation therapy (cytotoxic) within 3 years prior to
study vaccination.

- Have known active neoplastic disease or a history of any hematologic malignancy.

- Have known HIV, hepatitis B, or hepatitis C infection.

- Have known hypersensitivity or allergy to eggs, egg or chicken protein,
squalene-based adjuvants, or other components of the study vaccine.

- Have a history of severe reactions following previous immunization with licensed or
unlicensed influenza virus vaccines.

- Have a history of Guillain-Barré Syndrome.

- Have a history of neuralgia, paresthesia, neuritis, convulsions, or encephalomyelitis
within 90 days prior to study vaccination.

- Have a history of autoimmune disease, including but not limited to neuroinflammatory
diseases, vasculitis, clotting disorders, dermatitis, arthritis, thyroiditis, or
muscle, liver or kidney disease.

- Have a history of alcohol or drug abuse within 5 years prior to study vaccination.

- Have any diagnosis, current or past, of schizophrenia, bipolar disease, or other
psychiatric diagnosis that may interfere with subject compliance or safety
evaluations.

- Have been hospitalized for psychiatric illness, history of suicide attempt, or
confinement for danger to self or others within 10 years prior to study vaccination.

- Have taken oral or parenteral corticosteroids of any dose within 30 days prior to
study vaccination.

- Have taken high-dose inhaled corticosteroids within 30 days prior to study
vaccination. High-dose defined as >800mcg/day of beclomethasone dipropionate CFC or
equivalent.

- Received any licensed live vaccine within 30 days or any licensed inactivated vaccine
within 14 days prior to the first study vaccination or planned receipt of any vaccine
from the first study vaccination through the follow-up visit at approximately 21 days
after the last study vaccination. This is inclusive of licensed seasonal influenza
vaccines.

- Received immunoglobulin or other blood products (with exception of Rho D
immunoglobulin) within 90 days prior to study vaccination.

- Received an experimental agent (vaccine, drug, biologic, device, blood product, or
medication) within 30 days prior to the first study vaccination, or expects to
receive an experimental agent other than from participation in this study during the
13-month study period.

- Are participating or plan to participate in another clinical trial with an
interventional agent (licensed or unlicensed vaccine, drug, biologic, device, blood
product, or medication) during the 13-month study period.

- Prior participation in a clinical trial of influenza A/H7 vaccine and assigned to a
group receiving influenza A/H7 vaccine (does not apply to documented placebo
recipients) or have a history of A/H7 actual or potential exposure or infection prior
to the first study vaccination.

- Plan to travel outside the U.S. (continental U.S., Hawaii and Alaska) in the time
between the first study vaccination and 42 days after the first study vaccination.

- Female subjects who are breastfeeding or plan to breastfeed at any given time from
the first study vaccination until 30 days after their last study vaccination.